Cita APA (7a ed.)

A, U., K, W., P, W., D, O., & M, S. (2019). CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFβ-induced HSC-T6 cells activation. Dove Medical Press.

Cita Chicago Style (17a ed.)

A, Ullah, Wang K, Wu P, Oupicky D, y Sun M. CXCR4-targeted Liposomal Mediated Co-delivery of Pirfenidone and AMD3100 for the Treatment of TGFβ-induced HSC-T6 Cells Activation. Dove Medical Press, 2019.

Cita MLA (8a ed.)

A, Ullah, et al. CXCR4-targeted Liposomal Mediated Co-delivery of Pirfenidone and AMD3100 for the Treatment of TGFβ-induced HSC-T6 Cells Activation. Dove Medical Press, 2019.